+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-01-19Number of Pages: 138

Endocrine Testing Market - Global Industry Analysis, Size, Share, Growth Trends and Forecast, 2015 - 2023

Global Endocrine Testing Market: Snapshot 

Endocrine testing refers to a group of tests performed to assess the overall function of the patient’s endocrine system. The release of hormones is linked to a variety of diseases, which makes them a solid indicator to reveal the nature and extent of diseases. The rising awareness about the solid connection between hormones and diseases has led to steady growth of the global endocrine testing market in the recent past. The market is expected to rise to a valuation of US$12.8 bn by the end of 2023, exhibiting a robust 8.50% CAGR between 2015 and 2023. 

Rising Incidence of Diabetes to Propel Demand for Endocrine Testing 

One of the key drivers for the global endocrine testing market is the rising number of patients suffering from diabetes. The crucial role played by insulin in the development and post-diagnostic management of diabetes makes it the key segment of the global endocrine testing market. The prevalence of diabetes is driven by the rising consumption of sugary foods across the world, accompanied by the widespread adherence to a sedentary lifestyle, particularly in developed regions such as North America and Europe. 

The rising prevalence of obesity is another major factor contributing to the growth of the global endocrine testing market. Obesity can often be caused by hormonal imbalance, the treatment for which requires endocrine testing. Obesity is also a contributing factor to the rising incidence of diabetes, as it promotes a sedentary lifestyle and is usually accompanied by excessive consumption of high-sugar food. 

On the other hand, the high costs of some advanced endocrine testing technologies are a major restraint against the global endocrine testing market. Despite their utility in the diagnosis of a variety of diseases, endocrine testing remains unaffordable for a significant part of the population in developing regions, which is unlikely to change in the near future. The lack of general awareness about healthcare in underdeveloped regions has also held back the growth of the global endocrine testing market. 

Rapid Growth of Endocrine Testing Market Expected in Asia Pacific 

Geographically, the global endocrine testing market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The presence of leading healthcare industry players in North America and Europe has resulted in steady dominance of these two regions in the global endocrine testing market. The rising awareness among the general population in countries such as the U.S., Canada, the U.K., Germany, etc. regarding the importance of endocrine testing is likely to keep these the two leading regional endocrine testing markets in the coming years. 

Nevertheless, the endocrine testing market is expected to exhibit rapid growth in Asia Pacific in the coming years. The rising prevalence of diabetes in Southeast Asia is a major driver for the endocrine testing market in Asia Pacific. In addition to this, the rising government support to the healthcare sector in countries such as India, Thailand, China, Australia, Japan, and South Korea is likely to be a key factor in the development of the Asia Pacific endocrine testing market. 

By end use, commercial laboratories are likely to remain the dominant segment of the global endocrine testing market in the coming years. Hospitals, physician offices, ambulatory care centers, and home-based testing are the other significant end uses of endocrine testing techniques. The convenience of outsourcing testing procedures to commercial laboratories is the key factor driving their demand in the global endocrine testing market. 

Key players in the global endocrine testing market include Bio-Rad Laboratories Inc., Agilent Technologies, Biomedical Diagnostics, Abbott Laboratories, LabCorp, F. Hoffman-La Roche Ltd., Thermo Fisher Scientific Inc., and Siemens AG. Of these, Abbott Laboratories and F. Hoffman-La Roche are likely to continue as the dominant leaders in the global endocrine testing market through the forecast period.

The global endocrine testing market has been broadly segmented on the basis of selected tests, diagnostic technologies, end-users, and geography. This report studies the current scenario as well as future market potential for endocrine testing globally. This report comprises an elaborate executive summary, which includes a market snapshot on market dynamics of various segments and sub-segments in a precise manner. Moreover, executive summary comprises waterfall diagram, which reflects the market size of various segments in descending order.

A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global endocrine testing market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, Porter’s Five Forces analysis, and market share analysis by key players (%) operating in the endocrine testing market.

Based on test, the global endocrine testing market has been segmented into estradiol (E2), Follicle Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), Luteinizing hormone (LH), Dehydroepiandrosterone sulfate (DHEAS), progesterone, testosterone, Thyroid Stimulating Hormone (TSH), prolactin, cortisol and insulin tests. The market for these tests has been extensively analyzed based on consistency, effectiveness, and sales revenue of the various products developed by the manufacturers. The market size and forecast in terms of USD million for each type has been provided for the period from 2013 to 2023. The report on the endocrine testing market also provides compound annual growth rate (CAGR %) for each of the market segments mentioned above for the forecast period from 2015 to 2023, considering 2014 as the base year.

Based on diagnostic technology, the global endocrine testing market has been segmented into five major technologies such as: tandem mass spectrometry, immunoassay, monoclonal and polyclonal antibody, sensor, and clinical chemistry technologies. The market for these types has been extensively analyzed based on consistency, effectiveness, and sales revenue of the various products developed by the manufacturers. The market size and forecast in terms of USD million for each product (category) has been provided for the period from 2013 to 2023. The report on the tissue engineered skin substitutes market also provides compound annual growth rate (CAGR %) for each of the market segments mentioned above for the forecast period from 2015 to 2023, considering 2014 as the base year.

The end user segmentation elucidates the global endocrine testing market by various end users that includes hospitals, commercial laboratories, ambulatory health care centers, home based tests and physician’s offices. The market for these types has been extensively analyzed based on consistency, effectiveness, and sales revenue of the various products developed by the manufacturers. The market size and forecast in terms of USD million for each product (category) has been provided for the period from 2013 to 2023. The report on the endocrine testing market also provides compound annual growth rate (CAGR %) for each of the market segments mentioned above for the forecast period from 2015 to 2023, considering 2014 as the base year.

Geographically, the global endocrine testing market has been categorized into North America, Europe, Asia Pacific, and Rest of the World. The market size and forecast for each of these regions have been provided for the period from 2013 to 2023 along with CAGR (%) for the forecast period from 2013 to 2023. The research study also incorporates the competitive scenario of major players in these regions.

A list of recommendations have been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of major players in the endocrine testing market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include F-Hoffmann La Roche, Ltd., Abbott Laboratories, DiaSorin, Agilent Technologies, Siemens Healthcare, Thermo Fisher Scientific, AB SCIEX LLC, Bio Rad Laboratories, Lab Corporation, bioMerieux, Sysmex Corporation, Ortho-clinical Diagnostics, Quest Diagnostics and Biomedical Diagnostics.

The global endocrine testing market is segmented as follows:

Global Endocrine Testing Market, by Test, 2013-2023 (USD Million)

  • Estradiol (E2) Test
  • Follicle Stimulating Hormone (FSH) Test
  • Human Chorionic Gonadotropin (hCG) Test
  • Luteinizing Hormone (LH) Test
  • Dehydroepiandrosterone sulfate (DHEAS) Test
  • Progesterone Test
  • Testosterone Test
  • Thyroid Stimulating Hormone (TSH) Test
  • Prolactin Test
  • Cortisol Test
  • Insulin Test
  • Others (Gastrin, Thymosin, Secretin, etc.)

Global Endocrine Testing Market, by Diagnostic Technology, 2013 – 2023 (USD Million)

  • Tandem Mass spectrometry
  • Immunoassay (Enzyme immunoassays, Radioimmunoassays  (RIA)) Technologies
  • Monoclonal and Polyclonal Antibody Technologies
  • Sensor (Electrochemical, Biosensors, etc.) Technologies
  • Clinical Chemistry Technologies
  • Others (Liquid Chromatography + Mass Spectrometry (LC-MS)

Global Endocrine Testing Market, by End User, 2013 – 2023 (USD Million)

  • Hospitals
  • Commercial Laboratories
  • Ambulatory Care Centers
  • Home Based Tests
  • Physician Offices

Global Endocrine Testing Market, by Geography, 2013 – 2023 (USD Million)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Rest of the World (RoW)


 
 
Back To Top